Products Elbasvir was approved in many countries in 2016 as a fixed-dose combination with the protease inhibitor grazoprevir in film-coated tablet form (Zepatier). Structure and properties Elbasvir (C49H55N9O7, Mr = 882.0 g/mol) Effects Elbasvir (ATC J05AX68) has antiviral properties. The effects are due to binding to the viral protein NS5A (Non-Structural Protein 5A). Unlike other … Elbasvir
Products Ombitasvir was approved in the EU and many countries in 2014 in film-coated tablet form (Viekirax, combination drug). Structure and properties Ombitasvir (C50H67N7O8, Mr = 894.1 g/mol) Effects Ombitasvir (ATC J05AX66) has antiviral properties against HCV virus. The effects are due to binding to the viral protein NS5A (Non-Structural Protein 5A). Unlike other HCV … Ombitasvir
Products Direct antiviralia are commercially available as drugs in the form of tablets, capsules, solutions, and creams, among others. The first antiviral agent was approved in the 1960s (idoxuridine). Structure and properties Antivirala are a large group of drugs and have no uniform chemical structure. However, groups can be formed, such as the nucleoside analogs. … Antiviralia
Symptoms Most patients have no symptoms. The disease may manifest as fatigue, nausea, loss of appetite, muscle and joint pain, and weight loss. Potential longer-term dangerous complications of chronic infection that can develop over years include cirrhosis and liver cancer. This eventually often makes liver transplantation necessary. Causes The cause of the symptoms is infection … Hepatitis C Symptoms, Causes and Treatment
Products Pibrentasvir was approved in the United States, many countries, and the EU in 2017 as a fixed-dose combination with glecaprevir in film-coated tablet form (Maviret). Structure and properties Pibrentasvir (C57H65F5N10O8, Mr = 1113.2 g/mol) exists as a white to slightly yellow crystalline powder. Effects Pibrentasvir has antiviral properties. The effects are due to binding … Pibrentasvir
Products Velpatasvir was approved in 2016 in fixed combination with the HCV polymerase inhibitor sofosbuvir in film-coated tablet form (Epclusa, Gilead). Another fixed combination is Vosevi with sofosbuvir and voxilaprevir. Structure and properties Velpatasvir (C49H54N8O8, Mr = 883.0 g/mol) Effects Velpatasvir has antiviral properties. The effects are due to binding to the viral protein NS5A … Velpatasvir
Products Daclatasvir was approved in the EU in 2014 and in many countries in 2015 in film-coated tablet form (Daklinza, Bristol-Myers Squibb). Structure and properties Daclatasvir (C40H50N8O6, Mr = 738.9 g/mol) is present in the drug product as daclatasvir dihydrochloride. Effects Daclatasvir (ATC J05AX14) has antiviral properties. The effects are due to binding to the … Daclatasvir
Products Ledipasvir is approved as a fixed combination with sofosbuvir in the form of film-coated tablets (Harvoni). It was released in many countries in 2014. The high price of the drug is controversial (see Sofosbuvir). Cheaper generics are available in India: MyHep LVIR. Structure and properties Ledipasvir (C49H54F2N8O6, Mr = 888.9 g/mol) is practically insoluble … Ledipasvir
